Fulgent Genetic (NASDAQ:FLGT) is scheduled to announce its earnings results after the market closes on Monday, November 6th.
Fulgent Genetic (NASDAQ:FLGT) last announced its earnings results on Monday, August 7th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $5.03 million. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. On average, analysts expect Fulgent Genetic to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Fulgent Genetic (NASDAQ FLGT) opened at $3.46 on Friday.
Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Credit Suisse Group lowered their price target on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price target (down previously from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Finally, ValuEngine upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.
In other news, CFO Paul Kim sold 6,134 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $5.71, for a total value of $35,025.14. Following the completion of the transaction, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 58.80% of the company’s stock.
About Fulgent Genetic
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
What are top analysts saying about Fulgent Genetic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fulgent Genetic and related companies.